JP2019503990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503990A5 JP2019503990A5 JP2018525755A JP2018525755A JP2019503990A5 JP 2019503990 A5 JP2019503990 A5 JP 2019503990A5 JP 2018525755 A JP2018525755 A JP 2018525755A JP 2018525755 A JP2018525755 A JP 2018525755A JP 2019503990 A5 JP2019503990 A5 JP 2019503990A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 116
- 125000000539 amino acid group Chemical group 0.000 claims 51
- 150000001413 amino acids Chemical class 0.000 claims 22
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000007562 Serum Albumin Human genes 0.000 claims 6
- 108010071390 Serum Albumin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 5
- 102220041913 rs587780812 Human genes 0.000 claims 5
- 150000005829 chemical entities Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102220608040 Beta-defensin 1_R30T_mutation Human genes 0.000 claims 3
- 102220481238 Thymocyte selection-associated high mobility group box protein TOX_F29A_mutation Human genes 0.000 claims 3
- 102220036452 rs137882485 Human genes 0.000 claims 3
- -1 molecule Chemical class 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204262A JP7453206B2 (ja) | 2015-11-18 | 2021-12-16 | 改良された血清アルブミン結合剤 |
| JP2024034704A JP2024063213A (ja) | 2015-11-18 | 2024-03-07 | 改良された血清アルブミン結合剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256841P | 2015-11-18 | 2015-11-18 | |
| US62/256,841 | 2015-11-18 | ||
| US201662335746P | 2016-05-13 | 2016-05-13 | |
| US62/335,746 | 2016-05-13 | ||
| US201662349294P | 2016-06-13 | 2016-06-13 | |
| US62/349,294 | 2016-06-13 | ||
| PCT/EP2016/077973 WO2017085172A2 (en) | 2015-11-18 | 2016-11-17 | Improved serum albumin binders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204262A Division JP7453206B2 (ja) | 2015-11-18 | 2021-12-16 | 改良された血清アルブミン結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019503990A JP2019503990A (ja) | 2019-02-14 |
| JP2019503990A5 true JP2019503990A5 (enExample) | 2019-12-19 |
| JP7046804B2 JP7046804B2 (ja) | 2022-04-04 |
Family
ID=57326420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525755A Active JP7046804B2 (ja) | 2015-11-18 | 2016-11-17 | 改良された血清アルブミン結合剤 |
| JP2021204262A Active JP7453206B2 (ja) | 2015-11-18 | 2021-12-16 | 改良された血清アルブミン結合剤 |
| JP2024034704A Pending JP2024063213A (ja) | 2015-11-18 | 2024-03-07 | 改良された血清アルブミン結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204262A Active JP7453206B2 (ja) | 2015-11-18 | 2021-12-16 | 改良された血清アルブミン結合剤 |
| JP2024034704A Pending JP2024063213A (ja) | 2015-11-18 | 2024-03-07 | 改良された血清アルブミン結合剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11332519B2 (enExample) |
| EP (1) | EP3377525A2 (enExample) |
| JP (3) | JP7046804B2 (enExample) |
| CN (3) | CN108473564B (enExample) |
| AU (2) | AU2016357460B2 (enExample) |
| CA (1) | CA3005488A1 (enExample) |
| WO (1) | WO2017085172A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2723769T4 (da) | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| IL295534B2 (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable sites |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| CN108350069B (zh) | 2015-10-30 | 2021-11-12 | 埃博灵克斯股份有限公司 | 针对il-23的多肽 |
| CN110177809B (zh) | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | 能够结合CD123和TCRα/β的T细胞募集多肽 |
| KR102717656B1 (ko) * | 2017-05-31 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 |
| TW202417517A (zh) | 2017-06-02 | 2024-05-01 | 德商麥克專利有限公司 | 與ｍｍｐ１３結合之免疫球蛋白 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| CN112409480B (zh) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | 结合血清白蛋白的蛋白及其用途 |
| IL293554A (en) * | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| CA3163910A1 (en) | 2019-12-09 | 2021-06-17 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| US12428480B2 (en) * | 2019-12-11 | 2025-09-30 | Cullinan Therapeutics, Inc. | Anti-CD19 antibodies and multi-specific binding proteins |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| MX2022012278A (es) | 2020-03-30 | 2022-10-27 | Ablynx Nv | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. |
| BR112023005273A2 (pt) | 2020-09-25 | 2023-04-25 | Ablynx Nv | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l |
| KR20230123495A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드 |
| KR20230123497A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
| IL303740A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| TW202342508A (zh) | 2021-12-17 | 2023-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽 |
| WO2023242247A1 (en) | 2022-06-14 | 2023-12-21 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| CN120077065A (zh) | 2022-07-27 | 2025-05-30 | 阿布林克斯有限公司 | 与新生儿Fc受体的特定表位结合的多肽 |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| TW202444749A (zh) | 2023-01-09 | 2024-11-16 | 美商奧迪希治療公司 | 抗tnfr2抗原結合蛋白及其用途 |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| AR132699A1 (es) | 2023-05-17 | 2025-07-23 | Odyssey Therapeutics Inc | Anticuerpos de dominio único modificados |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AU2024308381A1 (en) | 2023-06-29 | 2025-11-20 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| WO2025061919A1 (en) | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| CA2588892A1 (en) | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| EP2949668B1 (en) * | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| BRPI0609797B8 (pt) | 2005-05-20 | 2021-05-25 | Ablynx Nv | nanocorpos melhorados para o tratamento de desordens mediadas por agregação |
| JP2009519011A (ja) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| EA200801166A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| CA2640066A1 (en) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| JP6034023B2 (ja) | 2008-05-16 | 2016-11-30 | アブリンクス エン．ヴェー． | Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物 |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| SG177601A1 (en) | 2009-07-16 | 2012-02-28 | Glaxo Group Ltd | Improved anti-serum albumin binding single variable domains |
| EP3466972A1 (en) * | 2011-06-23 | 2019-04-10 | Ablynx NV | Serum albumin binding proteins |
| DK2723769T4 (da) * | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| EA027160B1 (ru) * | 2011-08-17 | 2017-06-30 | Глаксо Груп Лимитед | Модифицированные белки и пептиды |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| IL295534B2 (en) * | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable sites |
| JP6929786B2 (ja) * | 2015-04-02 | 2021-09-01 | アブリンクス エン．ヴェー． | 強力な抗ｈｉｖ活性を有する二重特異性ｃｘｃｒ４−ｃｄ４ポリペプチド |
| CN108884162A (zh) * | 2015-11-10 | 2018-11-23 | 汉堡-埃普多夫大学医学中心 | 针对cd38的抗原结合多肽 |
| KR102220275B1 (ko) * | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| MX2018006243A (es) * | 2015-11-18 | 2018-11-09 | Merck Sharp & Dohme | Proteinas de union a pd1/ctla4. |
| EA038179B1 (ru) * | 2015-11-18 | 2021-07-20 | Мерк Шарп И Доум Корп. | Ctla4-связывающие вещества |
-
2016
- 2016-11-17 CA CA3005488A patent/CA3005488A1/en active Pending
- 2016-11-17 CN CN201680079196.5A patent/CN108473564B/zh active Active
- 2016-11-17 CN CN202210310096.6A patent/CN114605530B/zh active Active
- 2016-11-17 JP JP2018525755A patent/JP7046804B2/ja active Active
- 2016-11-17 CN CN202510665720.8A patent/CN120535622A/zh active Pending
- 2016-11-17 WO PCT/EP2016/077973 patent/WO2017085172A2/en not_active Ceased
- 2016-11-17 EP EP16797568.9A patent/EP3377525A2/en active Pending
- 2016-11-17 AU AU2016357460A patent/AU2016357460B2/en active Active
- 2016-11-17 US US15/774,662 patent/US11332519B2/en active Active
-
2021
- 2021-12-16 JP JP2021204262A patent/JP7453206B2/ja active Active
-
2022
- 2022-04-19 US US17/723,543 patent/US20220380445A1/en active Pending
-
2023
- 2023-09-12 AU AU2023229506A patent/AU2023229506A1/en active Pending
-
2024
- 2024-03-07 JP JP2024034704A patent/JP2024063213A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503990A5 (enExample) | ||
| JP2024063213A5 (enExample) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2018537421A5 (enExample) | ||
| JP2020515518A5 (enExample) | ||
| JP2020536888A5 (enExample) | ||
| JP2021191763A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| AU2023200113A1 (en) | Improved TNF binders | |
| JP2014513953A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2017529097A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2016508153A5 (enExample) | ||
| JP2017515815A5 (enExample) | ||
| JP2019506839A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2005503789A5 (enExample) | ||
| JP2016524463A5 (enExample) | ||
| JP2012500020A5 (enExample) | ||
| JPWO2020069028A5 (enExample) | ||
| JP2014519318A5 (enExample) |